Assessing Labcorp (LH) Valuation After AI Pathology Rollout With PathAI

AI driven pathology rollout puts Labcorp Holdings (LH) in focus

Labcorp Holdings (LH) is back on investors’ radar after expanding its collaboration with PathAI. The companies plan to roll out the FDA cleared AISight Dx digital pathology platform across Labcorp’s national anatomic pathology network.

See our latest analysis for Labcorp Holdings.

Labcorp’s 1 month share price return of 6.99% and year to date share price return of 13.37% suggest momentum has been building, while the 5 year total shareholder return of 43.95% points to a solid longer term record.

If AI enabled diagnostics are on your radar after this news, it could be worth scanning the market with our screener of 27 healthcare AI stocks as a starting list of ideas.

With Labcorp trading at $285.30, below the average analyst price target and an estimated intrinsic value, the key question is whether that gap signals a potential opportunity or if the market already reflects future growth.

Most Popular Narrative: 5% Undervalued

The most followed narrative puts Labcorp Holdings’ fair value at $300.18, a touch above the last close at $285.30, which frames today’s AI driven pathology news in a valuation context.

The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings.

Read the complete narrative.

Curious what sits behind that valuation gap? The narrative focuses on expectations for revenue trends, margin performance, and a future earnings multiple that reflects Labcorp’s role in complex testing.

Result: Fair Value of $300.18 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, tariffs, regulatory shifts like PAMA, and tougher pricing pressure in diagnostics could squeeze margins and challenge the earnings path behind that 5% undervalued case.

Find out about the key risks to this Labcorp Holdings narrative.

Next Steps

With mixed sentiment running through this update, it makes sense to check the numbers yourself sooner rather than later and weigh both sides of the story, including 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this update has sharpened your focus, do not stop at one stock. Use the tools at your fingertips to compare, contrast, and stress test your next move.

• Target quality first by scanning companies with strong fundamentals and robust finances through our solid balance sheet and fundamentals stocks screener (42 results) so you are not guessing on stability.
• Hunt for pricing gaps by reviewing 56 high quality undervalued stocks that may offer a more attractive entry point than the broader market is currently pricing in.
• Prioritize resilience by checking 80 resilient stocks with low risk scores where business risk scores stay relatively low, helping you focus on steadier candidates for your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com